Bull and Bear

Bull and Bear

A professional investor coming to Molina today weighs two readings of the same facts. On one side is a mechanical bridge management has drawn from a depressed 2026 base of at least $5.00 in adjusted EPS to a $25.00 target in 2029 — a climb that, by management's own account, "requires only a modest improvement in the Medicaid rate and trend imbalance" [1]. On the other is a structural read: a re-based, policy-exposed managed-care aggregator now targeting a 2–3% pre-tax margin, whose premium base is falling for the first time in years. This chapter puts the two on the same facts and marks what would decide between them.

The catalyst: a bridge that does not need 88% back

The bull case is not a hope that the old economics return. It is arithmetic on the depressed base. Molina's adjusted EPS collapsed from $22.65 in 2024 to $11.03 in 2025, and 2026 is guided to at least $5.00 [2]. Against that trough, management's 2029 target of $25.00 in adjusted EPS is a roughly 70% compound growth rate — but the destination is only modestly above the $22.65 the company actually earned in 2024 [3].

Source: 2026 Investor Day — 2019–2026 actual/guided [4]; 2029 target [5]. 2026 and 2027 are floors (guidance "at least"); 2027 is the initial building-block level, not a point target.

What the bridge rests on matters more than its slope. The clean, near-term rungs are contractual and self-help, not a bet on the medical-cost cycle. Management's 2027 building blocks take the $5.00 base up by $1.50 as the $6 billion Florida CMS contract ramps, $1.00 as it exits the loss-making standalone Medicare Advantage prescription-drug (MAPD) product, and $2.00 from operating leverage — offset by a $1.50 drag from legacy Medicaid MCR and $1.50 of other embedded-earnings timing, for an initial 2027 level near $6.50 before any further rate improvement [6].

Source: 2026 Investor Day, 2027 Adjusted EPS Building Blocks [7].

The 2029 destination adds the slower-burning rungs: premium revenue growing about 15% a year to $64 billion, a pre-tax margin recovering roughly 150 basis points to 2–3%, plus M&A and buybacks [8]. Crucially, the consolidated medical care ratio in the 2029 plan is 91–92% — roughly where it runs today, not the ~88% it averaged for five years before the break [9]. The earnings recovery the bull is buying comes from a bigger book earning a permanently thinner spread, not from the spread returning to its old width — which is why the depressed multiple (Valuation and Buybacks) can rebuild earnings without the margin ever normalizing.

The bear: a thinner, more exposed business deserves a lower multiple

The structural read accepts the same bridge and draws the opposite conclusion. Management itself re-based its long-term margin down — the consolidated MCR target moved from 87.5–88.5% to 91–92%, and the pre-tax margin target from 4–5% to 2–3% (Margin Reset) [10]. A business that keeps two to three cents of pre-tax profit per premium dollar, sources three of every four of those dollars from Medicaid contracts it must periodically re-win, and is exposed to federal funding and eligibility policy more than to any competitor (Revenue Durability) is a different security than the mid-cycle compounder the pre-2025 multiple assumed. On that view, part of the 65% drawdown is a permanent re-rating, not a dislocation waiting to close.

The bear also has a fresh, uncomfortable fact: the top line has turned. Full-year 2026 premium is guided to about $42 billion, and management now expects same-store Medicaid membership to fall 6% this year, ending near 4.5 million members [11]. The government pie can shrink faster than share is won, and the largest policy headwinds — work requirements and funding cuts under the 2025 federal budget law — are scheduled to phase in across 2027–2029 (Revenue Durability), the very years the bridge needs revenue compounding at 15%.

The tension on shared facts

Each row below is a fact both sides accept; what separates bull from bear is the reading, and the last column is the observable that would settle it.

Sources: adjusted-EPS arc and 2029 outlook, 2026 Investor Day [12] [13]; Q1 2026 results and membership, Q1 FY2026 call [14] [15]; positioning per Ownership and Options; valuation per Valuation and Buybacks.

The first data point

The debate is not static. Molina's Q1 2026 — its first quarter reported since the plan was drawn — gave the bull the earliest supporting evidence. Consolidated MCR came in at 91.1% with adjusted EPS of $2.35 and a 1.6% adjusted pre-tax margin; Medicaid ran 92%, Medicare 89.8% [16]. More important than the level was the trend read: management said the post-pandemic acuity shift that drove the 2025 break "was behind us and would not recur is holding up," and reaffirmed a 5% medical-cost-trend assumption for the year [17]. Operating cash flow was positive at $1.1 billion, and several states had already granted off-cycle rate increases that would be upside to guidance [18].

Sources: share price as reported (Jul 16 2026); P/E derived from the $25 target [19]; Q1 2026 EPS and MCR, Q1 FY2026 call [20].

The bear's answer sits in the same transcript. Management called the quarter "solid under the circumstances" but explicitly declined to raise the year, choosing to "merely" reaffirm at least $5.00 and roughly $42 billion of premium, and noting earnings are front-loaded because the January Medicaid rate cycle and the Florida ramp fall unevenly across the year [21]. The embedded-earnings pipeline that anchors 2027 — about $2.50 per share from combined MAPD losses and Florida first-year costs "certain to be positive impacts" next year — is real, but by construction it is a 2027 event, not a 2026 one [22].

What decides it, and where the price sits

The two cases converge on the same set of checkable observables. A reader can track the bridge, quarter by quarter, against these:

Sources: rate/trend and membership items, Q1 FY2026 call [23] [24]; Florida and 2027 bridge, 2026 Investor Day [25]; Washington and policy per Revenue Durability.

The evidence, read together, points to a name that is priced for a partial recovery and has taken its first supportive step toward one. At $224.82 the market pays about 9 times the 2029 target and roughly 13 times a normalized result on today's revenue at the re-based margin — a multiple that already discounts something short of full delivery, so partial success re-rates the stock and outright failure is largely in the price. The bridge's near-term rungs (Florida, the MAPD exit, operating leverage) are contractual and more reliable than its margin-recovery rung, and Q1 2026 is a real, if single, data point that the cost trend has stopped worsening.

The strongest facts against that read are equally concrete and belong in the same breath. Management re-based its own margin targets downward and, given a favorable quarter, chose to reaffirm rather than raise — the behavior of a team that still sees wide outcomes. No insider has bought and no buyback has resumed through the entire drawdown (Ownership and Options), so the people closest to the numbers have not confirmed the recovery with capital. What would move the read: two or three quarters of consolidated MCR below the guided path, joined by off-cycle rate updates, would validate the modest rate improvement the bridge is built on; a lost Washington rebid or OBBBA-driven eligibility cuts would break the top-line leg that the whole $5-to-$25 climb assumes. The watch table above lists the observables that settle the case quarter by quarter; Q1 2026 is the first of them on the table, and it read to the bull side.